NORDIC NANOVECTOR CAPITAL MARKETS DAY 2016 TO HIGHLIGHT STRONG PROGRESS TOWARDS VISION OF BECOMING A SIGNIFICANT PLAYER IN HAEMATOLOGICAL CANCERS
Oslo, Norway, 31 May 2016
Today, Nordic Nanovector ASA (OSE: NANO) hosts a Capital Markets Day in Oslo to provide investors, analysts and press with the opportunity to learn more about the company’s lead antibody-radionuclide conjugate (ARC) product Betalutin®, a potential new treatment for non-Hodgkin’s lymphoma (NHL), its positioning in the NHL therapy market, development plans, as well as future opportunities for value creation based on its ARC platform.
The key takeways from today’s presentations are summarised below.
Prof. Luigi Zinzani (Associate Professor of Haematology at the Institute of Haematology “L. e A. Seràgnoli” at the University of Bologna and co-chair of Nordic Nanovector’s Scientific Advisory Board) provides an overview of the existing and emerging landscape of therapies for NHL. Current treatments include anti-CD20 immunotherapy, chemotherapy and radiotherapy, but there is no standard treatment beyond 2nd line. Betalutin®, a novel ARC, could provide a future treatment option for these patients, who relapse or become refractory to standard treatments.
Dr Arne Kolstad (a senior consultant in medical oncology and radiotherapy at Oslo University Hospital Radiumhospitalet and a member of Nordic Nanovector’s Scientific Advisory Board) describes how Betalutin® is specifically designed to deliver better treatment outcomes for NHL patients. Dr Kolstad also reviews the latest clinical findings from the ongoing Phase 1/2 trial (Lymrit 37-01) with Betalutin® in NHL patients, which were presented in April at the American Association of Cancer Research annual meeting. These data, combined with the fact that Betalutin® targets a different antigen than standard CD20 therapies, highlights its potential to be a novel, safe and effective therapy for B-cell malignancies.
Dr Marco Renoldi (Nordic Nanovector’s Chief Business Officer) outlines how the insights gained from extensive market research by the company have validated its clinical development strategy and will guide its future commercial strategy with Betalutin®. He also describes how these insights have led the company to define and understand the key steps that it needs to take to support a successful product launch.
Dr Jostein Dahle (Nordic Nanovector’s Chief Scientific Officer) provides a glimpse of R&D activities underway at Nordic Nanovector, designed to build an exciting pipeline of ARCs in the longer term. Dr Dahle will describe Betalutin®’s potential in 2nd line FL, particularly in combination with CD20-targeting immunotherapies. Beyond this, the company aims to leverage its expertise in ARCs and haematology with partners, such as the Paul Scherrer Institute, to identify opportunities for ARCs for other NHL indications.
Luigi Costa and Tone Kvåle (Nordic Nanovector’s CEO and CFO, respectively) wrap up the meeting with a presentation detailing the company’s overall strategy focused on maximizing shareholder value through the development of innovative targeted ARC therapies for patients with haematological cancers.
Nordic Nanovector’s key strategic priorities:
• Obtain approval for lead product Betalutin® in NHL – initially in 3rd line and 2nd line FL – with clinical trials on track and first filing expected in 1H 2019
• Advance the clinical development of Betalutin® in a second significant NHL indication, diffuse large B cell lymphoma (DLBCL)
• Selectively extend the company’s pipeline around its core expertise (ARCs and haematology) to enhance innovation and manage risk
• Take an opportunistic approach to partnership opportunities to access complementary technologies and expertise
• Independently commercialize Betalutin® and its pipeline products in major markets
• Leverage management/board expertise alongside efficient capital deployment to ensure the attainment of clinical and corporate objectives
All presentations are available at www.nordicnanovector.com in the section:
Investor Relations/Reports and Presentation/Capital Markets days/2016.
For further information, please contact:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
E-mail: ir@nordicnanovector.com
International Media Enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionclide-Conjugates (ARC) designed to improve upon a complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over USD 12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulator submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation to Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Tags: